Citadel Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Citadel Advisors’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-519,516	Closed	-$116M	–	12937
2025 Q4	$111M	Buy	519,516 +491,876	+1,780%	+$102M	0.02%	790
2025 Q3	$5.5M	Sell	27,640 -559,702	-95%	-$104M	﹤0.01%	4202
2025 Q2	$101M	Sell	587,342 -537,841	-48%	-$87.6M	0.02%	761
2025 Q1	$175M	Buy	1,125,183 +229,199	+26%	+$32.7M	0.03%	417
2024 Q4	$123M	Buy	895,984 +232,060	+35%	+$30.5M	0.02%	624
2024 Q3	$99.1M	Buy	663,924 +126,162	+23%	+$17M	0.02%	707
2024 Q2	$73.3M	Buy	537,762 +80,258	+18%	+$10.9M	0.01%	861
2024 Q1	$69.2M	Buy	457,504 +285,933	+167%	+$40.8M	0.01%	968
2023 Q4	$21.6M	Buy	171,571 +171,323	+69,082%	+$17.1M	﹤0.01%	1935
2023 Q3	$23.2K	Sell	248 -13,724	-98%	-$1.28M	﹤0.01%	12502
2023 Q2	$1.25M	Sell	13,972 -107,030	-88%	-$9.32M	﹤0.01%	6006
2023 Q1	$13M	Sell	121,002 -135,284	-53%	-$15.5M	﹤0.01%	2459
2022 Q4	$31.3M	Buy	256,286 +202,346	+375%	+$23.5M	0.01%	1518
2022 Q3	$5.57M	Sell	53,940 -3,248	-6%	-$308K	﹤0.01%	3691
2022 Q2	$5.32M	Buy	+57,188	New	+$5.39M	﹤0.01%	3686
2022 Q1	–	Sell	-52,026	Closed	-$6.03M	–	13532
2021 Q4	$7M	Buy	52,026 +42,848	+467%	+$6.37M	﹤0.01%	3720
2021 Q3	$1.46M	Sell	9,178 -280,497	-97%	-$38.4M	﹤0.01%	7144
2021 Q2	$38.1M	Buy	289,675 +174,760	+152%	+$23.3M	0.01%	1361
2021 Q1	$14.8M	Sell	114,915 -205,099	-64%	-$31.2M	﹤0.01%	2386
2020 Q4	$53.4M	Sell	320,014 -178,373	-36%	-$29.5M	0.01%	909
2020 Q3	$76.9M	Buy	498,387 +24,144	+5%	+$3.47M	0.02%	603
2020 Q2	$70.1M	Buy	474,243 +227,543	+92%	+$31.2M	0.03%	595
2020 Q1	$27.8M	Sell	246,700 -82,982	-25%	-$10.8M	0.01%	980
2019 Q4	$45.9M	Buy	329,682 +320,970	+3,684%	+$35.7M	0.02%	821
2019 Q3	$839K	Sell	8,712 -63,356	-88%	-$7.07M	﹤0.01%	5899
2019 Q2	$8.3M	Sell	72,068 -233,808	-76%	-$28M	﹤0.01%	2410
2019 Q1	$36M	Buy	305,876 +209,267	+217%	+$18.3M	0.02%	880
2018 Q4	$6.05M	Buy	96,609 +86,760	+881%	+$5.45M	﹤0.01%	2523
2018 Q3	$698K	Sell	9,849 -16,829	-63%	-$1.16M	﹤0.01%	6162
2018 Q2	$1.77M	Buy	+26,678	New	+$1.75M	﹤0.01%	4291
2017 Q4	–	Sell	-10,273	Closed	-$372K	–	7932
2017 Q3	$372K	Buy	+10,273	New	+$295K	﹤0.01%	5729
2016 Q1	–	Sell	-1,156	Closed	-$21K	–	6734
2015 Q4	$21K	Sell	1,156 -2,531	-69%	-$44.4K	﹤0.01%	7883
2015 Q3	$65K	Buy	+3,687	New	+$71.8K	﹤0.01%	7369
2015 Q2	–	Sell	-60,316	Closed	-$1.05M	–	8703
2015 Q1	$1.05M	Buy	+60,316	New	+$1.1M	﹤0.01%	3870

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Citadel Advisors's ASND Position: Q1 2026 in Review

Citadel Advisors sold out of Ascendis Pharma A/S (ASND) in Q1 2026, closing a stake of 519,516 shares — an estimated $116M sold.

Citadel Advisors first reported a position in ASND in Q1 2015 and held it in 34 quarters. The position peaked at $175M in Q1 2025. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

Citadel Advisors reported no remaining Ascendis Pharma A/S position as of Q1 2026 after selling out during the quarter.
Citadel Advisors sold 519,516 Ascendis Pharma A/S shares in Q1 2026, an estimated $116M.
Citadel Advisors first reported a position in Ascendis Pharma A/S in Q1 2015 and held it in 34 quarters.
Citadel Advisors's Ascendis Pharma A/S position peaked at $175M in Q1 2025.
273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.